Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice

Devi, Yengkhom Sangeeta; Mukherjee, Paushali; Yazdani, Syed Shams; Shakri, Ahmad Rushdi; Mazumdar, Suman; Pandey, Sunita; Chitnis, Chetan E.; Chauhan, Virander S.

doi:10.1016/j.vaccine.2007.04.080

Cited by 35 publications

(27 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recombinant PvMSP1 19 has also been tested in combination with PvDBPII in mice. Immunization with combination of PvDBPII and PvMSP1 19 formulated with the Montanide ISA 720 elicited high titer antibody responses against both antigens [64].…”

Section: P Vivax Merozoite Surface Proteinsmentioning

confidence: 99%

“…In a study of children aged 1-3 years residing in a malaria endemic region of Papua New Guinea, Stanisic et al [65] have shown that naturally acquired antibodies against the C-terminal Block II of PvMSP3␣ and the N-terminal domain of PvMSP9 are significantly associated with protection from symptomatic P. vivax malaria and prospective risk during 16 months of active follow-up. The region that contains Block II of PvMSP3␣ and the N-terminal region of PvMSP9, are highly conserved across P. vivax isolates [64]. In another study, high titer antibodies to interspecies conserved blocks 2-5 of PvMSP1 (PvMSP1 ICB2-5) were also found to be associated with clinical protection against P. vivax suggesting that other regions of PvMSP1 could also be considered for vaccine development [66].…”

Section: P Vivax Merozoite Surface Proteinsmentioning

confidence: 99%

See 1 more Smart Citation

Development of vaccines for Plasmodium vivax malaria

Müeller

Shakri

Chitnis

2015

Vaccine

Self Cite

View full text Add to dashboard Cite

Plasmodium vivax continues to cause significant morbidity outside Africa with more than 50% of malaria cases in many parts of South and South-east Asia, Pacific islands, Central and South America being attributed to P. vivax infections. The unique biology of P. vivax, including its ability to form latent hypnozoites that emerge months to years later to cause blood stage infections, early appearance of gametocytes before clinical symptoms are apparent and a shorter development cycle in the vector makes elimination of P. vivax using standard control tools difficult. The availability of an effective vaccine that provides protection and prevents transmission would be a valuable tool in efforts to eliminate P. vivax. Here, we review the latest developments related to P. vivax malaria vaccines and discuss the challenges as well as directions toward the goal of developing highly efficacious vaccines against P. vivax malaria.

show abstract

Section: P Vivax Merozoite Surface Proteinsmentioning

confidence: 99%

Section: P Vivax Merozoite Surface Proteinsmentioning

confidence: 99%

Development of vaccines for Plasmodium vivax malaria

Müeller

Shakri

Chitnis

2015

Vaccine

Self Cite

View full text Add to dashboard Cite

show abstract

“…Plasmodium Ags included in this study were as follows: PfMSP-1 19 (34), PfAMA-1 (35), PfEBA175 (PfF2) (36), DBL3X, DBL5ε, DBL6ε (37), Pv200L (PvMSP1 121-416 ) (38), PvMSP-1 19 (39), PvCSP-N, PvCSP-C, PvCSP-R (40), full-length PvCSP, full-length PvMSP-5 (41), PvDBP (RII) (42), PvLP1, and PvLP2 (43). In addition, three P. vivax vir genes were expressed using the cell-free Wheat Germ system (41) .…”

Section: Quantification Of Abs and Cytokinesmentioning

confidence: 99%

Pregnancy and Malaria Exposure Are Associated with Changes in the B Cell Pool and in Plasma Eotaxin Levels

Requena

Campo

Umbers

et al. 2014

The Journal of Immunology

Self Cite

View full text Add to dashboard Cite

Pregnancy triggers immunological changes aimed to tolerate the fetus, but its impact on B lymphocytes is poorly understood. In addition, exposure to the Plasmodium parasite is associated with altered distribution of peripheral memory B cell (MBC) subsets. To study the combined impact of high malaria exposure and pregnancy in B cell subpopulations, we analyzed PBMCs from pregnant and nonpregnant individuals from a malaria-nonendemic country (Spain) and from a high malaria-endemic country (Papua New Guinea). In the malaria-naive cohorts, pregnancy was associated with a significant expansion of all switched (IgD−) MBC and a decrease of naive B cells. Malaria-exposed women had more atypical MBC and fewer marginal zone–like MBC, and their levels correlated with both Plasmodium vivax– and Plasmodium falciparum–specific plasma IgG levels. Classical but not atypical MBC were increased in P. falciparum infections. Moreover, active atypical MBC positively correlated with proinflammatory cytokine plasma concentrations and had lower surface IgG levels than the average. Decreased plasma eotaxin (CCL11) levels were associated with pregnancy and malaria exposure and also correlated with B cell subset frequencies. Additionally, active atypical and active classical MBC expressed higher levels of eotaxin receptor CCR3 than the other B cell subsets, suggesting a chemotactic effect of eotaxin on these B cell subsets. These findings are important to understand immunity to infections like malaria that result in negative outcomes for both the mother and the newborn and may have important implications on vaccine development.

show abstract

“…Using reverse phase chromatography refolded PvRII elutes as a single, homogeneous product. The endotoxin content of purified PvRII was less than 25 EU per 25 μg using standard LAL assay [15,21]. Recombinant PvRII was formulated with either Alhydrogel [15], Montanide ISA 720 (Seppic, France) or AS02A Adjuvant System (GlaxoSmithKline Biologicals, Belgium) prior to immunization following manufacturers' protocols.…”

Section: Vaccine Formulation and Immunization Schedulementioning

confidence: 99%

Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques

Moreno

Caro-Aguilar

Yazdani

et al. 2008

Vaccine

View full text Add to dashboard Cite

The receptor-binding domain of Plasmodium vivax Duffy binding protein, region II (PvRII), is an attractive candidate for a vaccine against P. vivax malaria. Here, we have studied the safety and immunogenicity of recombinant PvRII in Macaca mulatta (rhesus monkeys). Recombinant PvRII with a C-terminal 6-histidine tag was expressed in E. coli, recovered from inclusion bodies, refolded into its functional conformation, purified to homogeneity and formulated with three adjuvants, namely, Alhydrogel, Montanide ISA 720 and the GSK proprietary Adjuvant System AS02A for use in immunogenicity studies. All the PvRII vaccine formulations tested were safe and highly immunogenic. The overall magnitude of the antibody response was significantly higher for both Montanide ISA 720 and AS02A formulations in comparison with Alhydrogel. Furthermore, there was a significant correlation between antibody recognition titers by ELISA and binding inhibition titers in in vitro binding assays. The PvRII vaccine formulations also induced IFN-γ recall responses that were identified using ex vivo ELISPOT assays. These results provide support for further clinical development of a vaccine for P. vivax malaria based on recombinant PvRII.

show abstract

Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice

Cited by 35 publications

References 44 publications

Development of vaccines for Plasmodium vivax malaria

Development of vaccines for Plasmodium vivax malaria

Pregnancy and Malaria Exposure Are Associated with Changes in the B Cell Pool and in Plasma Eotaxin Levels

Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques

Contact Info

Product

Resources

About